ClearLife Nasal Spray Lawsuit Update: Injuries, Recall Status, and Legal Options

The U.S. Food and Drug Administration (FDA) published the manufacturer’s warning that ClearLife contained microbial contamination potentially associated with Achromobacter bacteria. MediNatura warned that exposure could cause life-threatening infections, particularly in people with weakened immune systems.

Consumers should stop using recalled ClearLife nasal spray and follow the manufacturer’s refund instructions. Individuals who developed serious infections after using the product may have grounds for an individualized product-liability evaluation, depending on medical evidence and applicable law.

Quick Facts

• Product: ClearLife Allergy Nasal Spray, Extra Strength, 0.68 fl. oz. (20 mL).
• Recall: Nationwide expansion announced December 16, 2025, covering specified lots within expiration.
• Hazard: Microbial contamination potentially linked to Achromobacter, with risks of serious infection.
• FDA classification: Class I, recall D-0289-2026; no adverse events reported at the original announcement.

Latest News on the ClearLife Nasal Spray Recall

November 2026

A November 12, 2026 review of the FDA’s published recall announcement confirms MediNatura’s December 2025 expansion involving ClearLife Allergy Nasal Spray. The company identified microbial contamination potentially linked to Achromobacter at levels exceeding product specifications [1].

The November 2026 verification also identified the FDA’s openFDA enforcement record for ClearLife Allergy Nasal Spray, recall D-0289-2026. The record identifies the recall as Class I and provides the affected product information, distribution details, and recall classification [2].

FDA explains that enforcement classifications may be assigned after a manufacturer publicly announces a voluntary recall. A later classification therefore does not necessarily indicate a newly expanded recall or additional contamination findings [3].

The reviewed records confirm the original contamination warning and the regulatory classification. They do not establish a current cumulative injury count, completed product recovery totals, or the number of consumers who received refunds.

The manufacturer’s December 2025 refund instructions remain published in the FDA announcement. Their continued publication does not independently confirm whether MediNatura is currently processing recall-specific refund requests.

January 2026

The FDA’s January 2026 enforcement reporting identified ClearLife Allergy Nasal Spray under recall number D-0289-2026. The recall appeared in the January 14, 2026 Enforcement Report and was classified as Class I on January 15, 2026.

The enforcement record identifies the affected product and its nationwide distribution. Class I is the FDA’s most serious recall classification, reflecting the potential for serious adverse health consequences or death.

The classification describes the severity of the potential hazard. It does not establish that any particular consumer developed an infection or suffered permanent injury.

December 2025

On December 16, 2025, MediNatura expanded its nationwide ReBoost Nasal Spray recall to include ClearLife Allergy Nasal Spray. The expansion followed further investigation into microbial contamination affecting the products.

The company identified yeast, mold, and Achromobacter contamination in ReBoost. For ClearLife, MediNatura described microbial contamination that may be linked to Achromobacter, without identifying the organism with the same degree of certainty.

MediNatura stated that no adverse events associated with the recall had been reported at the time of the announcement. Consumers were instructed to discontinue use and seek refunds.

Dierbergs Markets separately published a December 15, 2025 product-removal notice involving ClearLife and ReBoost nasal sprays. Customers were directed to stop using affected products and return them for refunds [4].

Event	Month/Year	Type	Status	Source	Notes
ClearLife recall information review	November 2026	Regulatory review	Reviewed	[1]	Original contamination warning confirmed
FDA enforcement record review	November 2026	Regulatory records	Reviewed	[2]	Specific ClearLife record identified
Class I recall classification	January 2026	Drug recall classification	Classified	[2]	Recall D-0289-2026
Expanded nationwide recall	December 2025	Manufacturer recall	Announced	[1]	ClearLife added to existing recall
Dierbergs product removal	December 2025	Retail recall notice	Published	[4]	Retail returns and refunds offered

What Is the ClearLife Nasal Spray Recall?

The recall involves ClearLife Allergy Nasal Spray, Extra Strength, distributed by MediNatura New Mexico Inc. of Albuquerque, New Mexico. The product was marketed as a homeopathic nasal spray for temporary relief of minor allergy symptoms.

Its advertised uses included relief from nasal congestion, sinus pressure, sneezing, runny nose, and itchy or watery eyes. The recalled spray was distributed nationwide through retailers and internet sales.

MediNatura expanded the recall after finding microbial contamination exceeding product specifications. The action reached the consumer level, requiring affected products to be removed from use.

Which ClearLife Nasal Spray Products Are Recalled?

The recall identifies ClearLife Allergy Nasal Spray, Extra Strength, packaged in a 20 mL bottle inside a white-and-green carton.

Product Identification

• Brand: ClearLife
• Product: Allergy Nasal Spray, Extra Strength
• Size: 0.68 fl. oz. (20 mL)
• NDC: 62795-4006-9
• UPC: 787647101887
• Recall number: D-0289-2026
• Affected lots: All lot numbers within the specified expiration range
• Expiration dates: December 2022 through December 2025

Consumers should compare their bottle and carton with the information in the FDA announcement. The recall covers the specified nasal spray, not every ClearLife product.

ClearLife allergy tablets are a different product and should not be assumed to be included under this particular recall.

What’s the Problem With ClearLife Nasal Spray?

The primary concern is microbial contamination in a product intended for administration inside the nose. Contamination may expose nasal tissues to microorganisms capable of causing infections.

MediNatura reported that contamination levels exceeded specifications and warned of potentially serious consequences for immunocompromised consumers.

The company described ClearLife contamination as potentially linked to Achromobacter. It did not establish that every recalled bottle contained that organism or caused an infection.

What Is Achromobacter?

Achromobacter is a genus of environmental bacteria found in water, soil, and other settings. Certain species can cause opportunistic infections, particularly in people with compromised immune systems or significant underlying medical conditions.

These organisms can be associated with respiratory and other infections. Severe cases may require hospitalization, laboratory testing, and antibiotic treatment.

However, the presence of microbial contamination does not automatically establish that an individual’s illness was caused by ClearLife. Medical records and microbiological findings may be necessary to evaluate causation.

What Health Risks Are Associated With Contaminated Nasal Spray?

MediNatura warned that use of the contaminated products could cause serious adverse health consequences, including life-threatening infections in immunocompromised individuals.

Potential symptoms and complications include:

• Nasal or sinus irritation
• Sinus pain, pressure, or inflammation
• Fever and other signs of infection
• Persistent respiratory symptoms
• Serious bacterial infections
• Hospitalization for severe infections
• Bloodstream infection or sepsis in severe cases

These are possible consequences of microbial exposure, not confirmed injuries among ClearLife users. No adverse events were reported in the manufacturer’s December 2025 announcement.

Consumers experiencing fever, worsening sinus pain, breathing difficulties, or other concerning symptoms after using the product should seek medical evaluation. Severe symptoms may require emergency treatment.

Why Is ClearLife Classified as a Class I Recall?

Class I is the FDA’s most serious recall classification. It applies when exposure to a violative product presents a reasonable probability of serious adverse health consequences or death.

The classification reflects the contamination hazard and the potential consequences for vulnerable consumers. It does not mean that deaths or severe infections have been confirmed.

FDA enforcement classifications are separate from manufacturer announcements and may be published after a company initiates a recall.

Have Injuries Been Reported From ClearLife Nasal Spray?

MediNatura reported no adverse events associated with the recall when it announced the expansion on December 16, 2025. The original notice did not identify confirmed infections, hospitalizations, or deaths attributed to ClearLife.

The reviewed sources do not establish a cumulative injury total through November 2026. The absence of reported injuries at the original announcement does not eliminate the potential contamination hazard.

Where Was ClearLife Nasal Spray Sold?

MediNatura distributed ClearLife nasal spray nationwide through retail stores and internet sales, including the manufacturer’s website.

Dierbergs Markets confirmed its removal of the affected product in December 2025. Consumers may also have purchased ClearLife through other retailers or directly from MediNatura.

The FDA announcement does not identify a total number of recalled bottles. Nationwide distribution should not be interpreted as evidence of a particular recall population.

What Should Consumers Do With Recalled ClearLife Nasal Spray?

Consumers should immediately discontinue use of recalled ClearLife nasal spray and identify affected bottles using the product name, NDC, UPC, and expiration information.

Individuals who experience symptoms potentially related to product use should contact their healthcare provider. Recalled products should not be used while attempting to determine whether a particular bottle is contaminated.

How Can Consumers Obtain a Refund?

MediNatura’s December 2025 recall announcement provided different refund instructions depending on the purchase location.

• Direct purchases: Email recall@medinatura.com to arrange a refund.
• Retail purchases: Return the recalled product to the original retailer.

These are the manufacturer’s published recall instructions. Consumers should confirm current processing arrangements with MediNatura or their retailer because continued refund availability has not been independently verified.

MediNatura Recall Contact Information

• Company: MediNatura New Mexico Inc.
• Telephone: 800-621-7644
• Email: recall@medinatura.com
• Hours listed in the recall: Monday through Friday, 8 a.m. to 5 p.m. Mountain Standard Time
• Official recall notice: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/medinatura-new-mexico-inc-expands-voluntary-nationwide-recall-reboost-nasal-spray-and-include

The recall remedy concerns refunds rather than product replacement. Any potential injury claim is a separate matter requiring legal evaluation.

Could MediNatura Be Liable for ClearLife Nasal Spray Injuries?

Product-liability law may allow injured consumers to pursue compensation when evidence establishes that a defective or contaminated product caused harm. Depending on applicable law, claims may involve manufacturing defects, inadequate warnings, negligence, or breach of warranty.

Liability depends on the product, alleged contamination, medical causation, and damages. A recall alone does not establish responsibility for an individual illness.

Laboratory findings, treatment records, and medical expert evaluations may be important when distinguishing product-related infections from other possible causes.

Who May Be Affected by the ClearLife Recall?

Consumers who purchased affected ClearLife Allergy Nasal Spray may qualify for the manufacturer’s recall remedy regardless of whether they developed symptoms.

People with compromised immune systems or serious underlying illnesses may face increased risks from microbial contamination. Anyone experiencing symptoms following use should obtain medical advice appropriate to their condition.

Consumers who suffered documented infections may have legal questions beyond the refund process.

Do I Qualify for a ClearLife Nasal Spray Lawsuit?

The following questions may help determine whether an incident warrants legal evaluation:

• Did you use ClearLife Allergy Nasal Spray, Extra Strength, included in the nationwide recall?
• Did you develop a serious infection or another medically documented condition after using the product?
• Did the illness require medical treatment, antibiotics, hospitalization, or additional care?
• Do you have product packaging, purchase records, medical documentation, or other supporting evidence?

Answering yes does not establish eligibility or guarantee compensation. An attorney can assess product identification, medical causation, damages, and applicable filing deadlines.

What Evidence Is Important in a ClearLife Nasal Spray Lawsuit?

Documentation may help identify the recalled product and determine whether its use contributed to an illness.

Relevant evidence includes:

• The nasal spray bottle and original carton
• Photographs showing NDC, UPC, and expiration date
• Purchase receipts or online order confirmations
• Medical records documenting symptoms and treatment
• Laboratory and microbiology test results
• Hospital and prescription records
• Communications with MediNatura or retailers
• Medical expenses and lost-income records

Consumers considering legal action may wish to obtain evidence-preservation guidance before discarding potentially relevant materials. The recalled nasal spray should remain out of use.

How Can Consumers Report an Adverse Reaction?

Consumers may report suspected adverse reactions or product-quality problems through the FDA’s MedWatch program. Reports can be submitted online or through the agency’s reporting forms.

MedWatch information is available at https://www.fda.gov/medwatch/report.htm. Consumers can request a reporting form by calling 800-332-1088.

An adverse-event report does not independently establish that ClearLife caused the reported condition. Reporting can nevertheless assist FDA safety monitoring.

What Compensation May Be Available?

Potential damages in qualifying product-liability claims may include medical expenses, hospitalization costs, future treatment, lost income, pain and suffering, permanent impairment, and other legally recognized losses.

Severe infections may involve extended treatment or rehabilitation. Compensation amounts vary by case. Past results do not guarantee future outcomes.

Speak With a ClearLife Nasal Spray Lawyer

If you developed a serious infection or another injury after using recalled ClearLife nasal spray, a product-liability attorney can review your medical records, product information, and treatment history. A free case review can help determine whether the evidence and applicable law support a potential injury claim.

How Does a ClearLife Nasal Spray Lawsuit Work?

1. Free case review. An attorney examines the recalled product, exposure history, injuries, and available documentation.
2. Investigation. Evidence may include FDA records, product packaging, purchase information, medical testing, and expert evaluations.
3. Filing. If supported by the evidence and applicable law, a product-liability claim may be filed against potentially responsible parties.
4. Discovery/negotiation. The parties exchange evidence, assess causation and damages, and may discuss settlement.
5. Resolution. A case may conclude through settlement, dismissal, court ruling, or trial.

Frequently Asked Questions

What is the ClearLife Nasal Spray Lawsuit?

The ClearLife Nasal Spray Lawsuit refers to potential product-liability claims involving injuries allegedly associated with recalled ClearLife Allergy Nasal Spray. The recall does not independently establish a filed lawsuit, nationwide settlement, or finding of liability.

Why was ClearLife nasal spray recalled?

MediNatura identified microbial contamination potentially associated with Achromobacter at levels exceeding specifications. The company warned that exposure could cause serious infections, especially among immunocompromised consumers.

Which ClearLife nasal spray products are recalled?

The recall includes ClearLife Allergy Nasal Spray, Extra Strength, in 20 mL bottles bearing NDC 62795-4006-9. All specified lots within the expiration range are included.

Is ClearLife nasal spray a Class I recall?

Yes. FDA enforcement information identifies recall D-0289-2026 as Class I, the agency’s highest-risk classification. This designation describes potential health consequences rather than confirmed injury totals.

Have injuries been reported from ClearLife nasal spray?

MediNatura reported no adverse events associated with the recall in December 2025. The reviewed information does not establish a subsequent cumulative injury count.

Can I file a ClearLife Nasal Spray Lawsuit?

A consumer who suffered a documented injury after using recalled ClearLife may have a potential claim if evidence supports product-related causation and legal liability. Eligibility depends on the circumstances, damages, and filing deadlines.

Is there a ClearLife nasal spray settlement?

The cited FDA and retailer records establish recall and refund information, not a nationwide injury settlement. The existence or outcome of any specific lawsuit requires separate court-record verification.

References

1. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/medinatura-new-mexico-inc-expands-voluntary-nationwide-recall-reboost-nasal-spray-and-include
2. https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0289-2026%22
3. https://www.fda.gov/safety/enforcement-reports/enforcement-report-information-and-definitions
4. https://www.dierbergs.com/swiftly/pages/product-recall-clearlife-reboost-nasal-spray